CCL2 and Sepsis: In a rat model of sepsis, LXA4 administration improved their survival and reduced systemic inflammation by lowering blood bacterial load and the plasma levels of inflammatory markers such as IL-6, monocyte chemotactic protein 1, and IL-10 (22).